BFM
KIN

Boothbay Fund Management’s Kindred Biosciences, Inc. KIN Stock Holding History

Boothbay Fund Management’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-16,610
Closed -$75K – 1328
2020
Q2 		$75K Buy
16,610
+6,410
+63% +$28.6K 0.01% 902
2020
Q1 		$41K Buy
+10,200
New +$86.6K ﹤0.01% 793

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boothbay Fund Management's KIN Position: Q3 2020 in Review

Boothbay Fund Management sold out of Kindred Biosciences, Inc. (KIN) in Q3 2020, closing a stake of 16,610 shares — an estimated $75K sold.

Boothbay Fund Management first reported a position in KIN in Q1 2020 and held it in 2 quarters. The position peaked at $75K in Q2 2020. 77 funds tracked by Wall St. Rank hold KIN as of Q3 2020.

  • Boothbay Fund Management reported no remaining Kindred Biosciences, Inc. position as of Q3 2020 after selling out during the quarter.
  • Boothbay Fund Management sold 16,610 Kindred Biosciences, Inc. shares in Q3 2020, an estimated $75K.
  • Boothbay Fund Management first reported a position in Kindred Biosciences, Inc. in Q1 2020 and held it in 2 quarters.
  • Boothbay Fund Management's Kindred Biosciences, Inc. position peaked at $75K in Q2 2020.
  • 77 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2020.

Based on Boothbay Fund Management's 13F filing for Q3 2020, filed 16 Nov 2020.